Literature DB >> 8798873

Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity.

K Akima1, H Ito, Y Iwata, K Matsuo, N Watari, M Yanagi, H Hagi, K Oshima, A Yagita, Y Atomi, I Tatekawa.   

Abstract

To enhance the selective delivery of antitumor drugs into regional lymph nodes and cancerous tissues via a hyaluronate (HA) receptor (CD44), we synthesized HA-mitomycin C complex and HA-epirubicin complex. To investigate the specific distribution of HA into regional lymph nodes and to evaluate the HA receptor on lewis lung carcinoma cells, we also synthesized 14C-labelled HA and fluorescent HA (FR-HA). The metabolic studies of 14C-HA and HA-epirubicin complex were performed in rats. The specific distribution of both compounds to the lymph nodes were observed after sc treatment. Internalization mechanisms of HA into carcinoma cells (lewis lung carcinoma) via HA receptor was investigated using fluorescent HA (FR-HA) in vitro. Internalization of FR-HA following binding to the cell surfaces was observed. HA-Mitomycin C (MMC) exhibited potent anti-metastatic effects against lewis lung carcinoma implanted in mice at an extremely low dose (0.01 mg/kg) whereas free MMC had no effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798873     DOI: 10.3109/10611869609046255

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  17 in total

Review 1.  Hyaluronan-CD44 interactions as potential targets for cancer therapy.

Authors:  Suniti Misra; Paraskevi Heldin; Vincent C Hascall; Nikos K Karamanos; Spyros S Skandalis; Roger R Markwald; Shibnath Ghatak
Journal:  FEBS J       Date:  2011-03-25       Impact factor: 5.542

2.  Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.

Authors:  Yi Luo; Nicole J Bernshaw; Zheng-Rong Lu; Jindrich Kopecek; Glenn D Prestwich
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

3.  Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer.

Authors:  Shuang Cai; Sharadvi Thati; Taryn R Bagby; Hassam-Mustafa Diab; Neal M Davies; Mark S Cohen; M Laird Forrest
Journal:  J Control Release       Date:  2010-04-18       Impact factor: 9.776

4.  Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma.

Authors:  Yu-Jin Jin; Ubonvan Termsarasab; Seung-Hak Ko; Jae-Seong Shim; Saeho Chong; Suk-Jae Chung; Chang-Koo Shim; Hyun-Jong Cho; Dae-Duk Kim
Journal:  Pharm Res       Date:  2012-08-11       Impact factor: 4.200

5.  Targeted drug delivery utilizing protein-like molecular architecture.

Authors:  Evonne M Rezler; David R Khan; Janelle Lauer-Fields; Mare Cudic; Diane Baronas-Lowell; Gregg B Fields
Journal:  J Am Chem Soc       Date:  2007-03-31       Impact factor: 15.419

Review 6.  Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.

Authors:  Virginia M Platt; Francis C Szoka
Journal:  Mol Pharm       Date:  2008-06-03       Impact factor: 4.939

7.  Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells.

Authors:  Coral O Omene; Jing Wu; Krystyna Frenkel
Journal:  Invest New Drugs       Date:  2011-05-03       Impact factor: 3.850

Review 8.  Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer.

Authors:  Suniti Misra; Vincent C Hascall; Roger R Markwald; Shibnath Ghatak
Journal:  Front Immunol       Date:  2015-05-06       Impact factor: 7.561

9.  Application of Collagen-Model Triple-Helical Peptide-Amphiphiles for CD44-Targeted Drug Delivery Systems.

Authors:  Margaret W Ndinguri; Alexander Zheleznyak; Janelle L Lauer; Carolyn J Anderson; Gregg B Fields
Journal:  J Drug Deliv       Date:  2012-11-14

Review 10.  Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery.

Authors:  Suniti Misra; Vincent C Hascall; Ilia Atanelishvili; Ricardo Moreno Rodriguez; Roger R Markwald; Shibnath Ghatak
Journal:  Int J Cell Biol       Date:  2015-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.